Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
Toxicol Mech Methods ; 27(7): 518-527, 2017 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-28552037

RESUMEN

DON (6-diazo-5-oxo-l-norleucine), a glutamine antagonist, was demonstrated to exhibit analgesic, antibacterial, antiviral and anticancer properties. The study was performed to characterize its in vitro and in vivo genetic toxicity potential. DON was tested in the bacterial reverse mutation assay (Ames test) using Salmonella typhimurium tester strains (TA98, TA100, TA1535 and TA1537) and Escherichia coli tester strain (WP2 uvrA) with and without S9 and also with reductive S9. In addition, DON was tested for the chromosome aberrations in Chinese hamster ovary (CHO) cells with or without S9 to evaluate the clastogenic potential. Furthermore, DON was also evaluated for its in vivo clastogenic activity by detecting micronuclei in polychromatic erythrocyte (PCE) cells in bone marrow collected from the male mice dosed intravenously with 500, 100, 10, 1 and 0.1 mg/kg at 24 and 48-h post-dose. The Ames mutagenicity assay showed no positive mutagenic responses. However, the in vitro chromosome aberration assay demonstrated dose dependent statistically positive increase in structural aberrations at 4 and 20-h exposure without S9 and also at 4-h exposure with S9. The in vivo micronucleus assay also revealed a statistically positive response for micronucleus formation at 500, 100 and 10 mg/kg at 24 and 48-h post-dose. Thus, DON appears to be negative in the Ames test but positive in the in vitro chromosome aberration assay and in the in vivo micronucleus assay. In conclusion, the results indicate DON is a genotoxic compound with a plausible epigenetic mechanism.


Asunto(s)
Compuestos Azo/toxicidad , Aberraciones Cromosómicas/efectos de los fármacos , Células Precursoras Eritroides/efectos de los fármacos , Glutamina/antagonistas & inhibidores , Mutágenos/toxicidad , Neurotransmisores/toxicidad , Norleucina/análogos & derivados , Activación Metabólica , Animales , Arocloros/farmacología , Compuestos Azo/administración & dosificación , Compuestos Azo/metabolismo , Células CHO , Cricetinae , Cricetulus , Relación Dosis-Respuesta a Droga , Contaminantes Ambientales/farmacología , Masculino , Mesocricetus , Ratones Endogámicos ICR , Pruebas de Micronúcleos , Microsomas Hepáticos/efectos de los fármacos , Microsomas Hepáticos/enzimología , Microsomas Hepáticos/metabolismo , Pruebas de Mutagenicidad , Mutágenos/administración & dosificación , Mutágenos/metabolismo , Neurotransmisores/administración & dosificación , Neurotransmisores/metabolismo , Norleucina/administración & dosificación , Norleucina/metabolismo , Norleucina/toxicidad , Ratas Sprague-Dawley , Pruebas de Toxicidad Aguda
2.
Regul Toxicol Pharmacol ; 72(1): 39-48, 2015 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-25728407

RESUMEN

l-Fucose is a natural monosaccharide present in mammals where it is found predominantly as an O-glycosidically linked component of glycoproteins, glycolipids, and oligosaccharides. It is also present in its free form in human breast milk (human milk monosaccharide). l-Fucose plays important roles in the development of the immune and nervous systems and is involved in cognitive function and memory formation. The human-identical milk monosaccharide l-fucose is therefore proposed for use in infant formulas to better simulate the free saccharides present in human breast milk. As part of the safety evaluation of l-fucose, a subchronic dietary toxicity study preceded by an in utero phase was conducted in Sprague-Dawley rats. l-Fucose was without maternal toxicity or compound-related adverse effects on female reproduction and general growth and development of offspring at a maternal dietary level up to 1%, equivalent to a dose of 1655 mg/kg body weight (bw)/day. During the subchronic phase, no compound-related adverse effects were observed in first generation rats at dietary levels of up to 1% (highest level tested), corresponding to doses of 516 and 665 mg/kg bw/day in males and females, respectively. l-Fucose was non-genotoxic in a series of in vitro genotoxicity/mutagenicity tests. These results support the safe use of l-fucose in infant formula and as a food ingredient at levels equivalent to those present in human breast milk.


Asunto(s)
Fucosa/administración & dosificación , Fórmulas Infantiles/farmacología , Leche Humana/metabolismo , Monosacáridos/efectos adversos , Animales , Femenino , Humanos , Lactante , Masculino , Pruebas de Mutagenicidad/métodos , Ratas , Ratas Sprague-Dawley , Reproducción/efectos de los fármacos , Seguridad
3.
Food Chem Toxicol ; 48(5): 1321-7, 2010 May.
Artículo en Inglés | MEDLINE | ID: mdl-20188778

RESUMEN

N-acetylglycine (NAGly) has been identified as a minor constituent of numerous foods. The current paper reports the outcome of in vitro and in vivo genotoxicity, acute oral and repeated dose dietary toxicology studies conducted with NAGly. No evidence of genotoxicity was observed with NAGly in vitro bacterial tester strains or in vivo bone marrow micronucleus studies conducted in mice. No mortalities or evidence of adverse effects were observed in Sprague-Dawley rats following acute oral gavage with NAGly at a dose of 2000 mg/kg of body weight or following repeated dose dietary exposure to NAGly at targeted doses of 100, 500, or 1000 mg/kg of body weight/day for 28 days. No biologically significant or test substance related differences were observed in body weights, feed consumption, or clinical pathology response variables in any of the treatment groups. Based on these results it was concluded that NAGly is not genotoxic or acutely toxic. Further, the no-observed adverse-effect-level (NOAEL) for systemic toxicity from repeated dose dietary exposure to NAGly was 898.9 mg/kg of body weight/day for male rats and 989.9 mg/kg of body weight/day for female rats.


Asunto(s)
Contaminantes Ambientales/toxicidad , Contaminación de Alimentos/análisis , Glicina/análogos & derivados , Acetilación , Administración Oral , Animales , Peso Corporal/efectos de los fármacos , Células de la Médula Ósea/efectos de los fármacos , ADN/efectos de los fármacos , Ingestión de Alimentos/efectos de los fármacos , Escherichia coli/efectos de los fármacos , Escherichia coli/genética , Femenino , Glicina/toxicidad , Longevidad , Masculino , Ratones , Ratones Endogámicos ICR , Micronúcleos con Defecto Cromosómico/inducido químicamente , Pruebas de Micronúcleos , Mutación/efectos de los fármacos , Nivel sin Efectos Adversos Observados , Proteínas/química , Ratas , Ratas Sprague-Dawley , Salmonella typhimurium/efectos de los fármacos , Salmonella typhimurium/genética , Pruebas de Toxicidad Aguda
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...